Brainstorm Cell Therapeutics (BCLI) –
-
Form 8-K BRAINSTORM CELL THERAPEU For: Apr 10
-
Brainstorm Cell Therapeutics (BCLI) Regains Nasdaq Compliance
-
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
-
Brainstorm Cell Therapeutics (BCLI) Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
-
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
-
Form 8-K BRAINSTORM CELL THERAPEU For: Apr 09
-
Brainstorm Cell Therapeutics (BCLI) Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
-
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
-
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
-
Form 424B5 BRAINSTORM CELL THERAPEU
-
Form 8-K BRAINSTORM CELL THERAPEU For: Apr 02
-
Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31
-
Form 8-K BRAINSTORM CELL THERAPEU For: Apr 01
-
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
-
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Lindborg Stacy
-
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Yablonka Uri
-
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Patlis Alla
-
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Lebovits Chaim
-
Brainstorm Cell Therapeutics (BCLI) to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference
-
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
-
Brainstorm Cell Therapeutics (BCLI) Submits SPA Request to FDA for US Phase 3b Trial of NurOwn
-
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
-
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
-
Form SC 13G/A BRAINSTORM CELL THERAPEU Filed by: Ness Kevin Dean
-
BCLI FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Brainstorm Cell, SolarEdge, and Barclays and Encourages Investors to Contact the Firm
-
BCLI DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action Commenced
-
BRAINSTORM SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Dis
-
Brainstorm Cell Therapeutics (BCLI) Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
-
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
-
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
-
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
-
Form 8-K BRAINSTORM CELL THERAPEU For: Dec 18
-
Brainstorm Cell Therapeutics (BCLI) Issues 2023 Letter to Shareholders
-
BrainStorm Issues 2023 Letter to Shareholders
-
ROSEN, THE FIRST FILING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
-
BRAINSTORM ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
-
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
-
BRAINSTORM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Direct
-
ROSEN, A RANKED AND LEADING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
-
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
-
BRAINSTORM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Dire
-
Brainstorm Cell Therapeutics (BCLI) Announces Outcome of FDA Meeting on NurOwn in ALS
-
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
-
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
-
BRAINSTORM SHAREHOLDER ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Disc
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
-
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
Back to BCLI Stock Lookup
